Literature DB >> 35444717

Paraganglioma in pregnancy: A case series and literature review.

Jade Eccles-Smith1, Stephanie Hopkins2, Jennifer Conn1,3,4, Stephanie Johnston5,6, Rebecca Szabo1,7,8, Sarah Price1,3,4, Alison Nankervis1,3,4.   

Abstract

Paragangliomas are rare neuroendocrine neoplasms which are often catecholamine-secreting and associated with familial syndromes. Described here are three women with a variety of pathology: isolated secretory paraganglioma diagnosed in pregnancy, secretory metastatic paraganglioma in pregnancy and non-secretory metastatic paraganglioma in pregnancy. Whilst paragangliomas are associated with morbidity and mortality during pregnancy, good maternal and fetal outcomes can be achieved through individualised care within the context of a multidisciplinary team. Although paragangliomas are associated with morbidity and mortality in pregnancy, good maternal and fetal outcomes can be achieved through individualised care within the context of a multidisciplinary team.
© The Author(s) 2021.

Entities:  

Keywords:  Paraganglioma; catecholamines; hypertension; pregnancy outcomes

Year:  2021        PMID: 35444717      PMCID: PMC9014550          DOI: 10.1177/1753495X211006012

Source DB:  PubMed          Journal:  Obstet Med        ISSN: 1753-495X


  48 in total

1.  Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials.

Authors:  L A Magee; E Elran; S B Bull; A Logan; G Koren
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2000-01       Impact factor: 2.435

2.  Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: an updated metaregression analysis.

Authors:  Peter von Dadelszen; Laura A Magee
Journal:  J Obstet Gynaecol Can       Date:  2002-12

3.  Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small-for-gestational-age newborns.

Authors:  H R Nakhai-Pour; E Rey; A Bérard
Journal:  Birth Defects Res B Dev Reprod Toxicol       Date:  2010-04

4.  Guidelines for diagnosis, treatment, and use of laparoscopy for surgical problems during pregnancy: this statement was reviewed and approved by the Board of Governors of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), September 2007. It was prepared by the SAGES Guidelines Committee.

Authors:  Hori Yumi
Journal:  Surg Endosc       Date:  2008-02-21       Impact factor: 4.584

5.  Perioperative α-receptor blockade in phaeochromocytoma surgery: an observational case series.

Authors:  H Groeben; B J Nottebaum; P F Alesina; A Traut; H P Neumann; M K Walz
Journal:  Br J Anaesth       Date:  2017-02       Impact factor: 9.166

6.  Expression of angiogenic growth factors in paragangliomas.

Authors:  R W Jyung; E E LeClair; R A Bernat; T S Kang; F Ung; M J McKenna; R S Tuan
Journal:  Laryngoscope       Date:  2000-01       Impact factor: 3.325

7.  Phaeochromocytoma diagnosed during labour.

Authors:  A N Strachan; P Claydon; J A Caunt
Journal:  Br J Anaesth       Date:  2000-10       Impact factor: 9.166

8.  Genetic testing in pheochromocytoma or functional paraganglioma.

Authors:  Laurence Amar; Jérôme Bertherat; Eric Baudin; Christiane Ajzenberg; Brigitte Bressac-de Paillerets; Olivier Chabre; Bernard Chamontin; Brigitte Delemer; Sophie Giraud; Arnaud Murat; Patricia Niccoli-Sire; Stéphane Richard; Vincent Rohmer; Jean-Louis Sadoul; Laurence Strompf; Martin Schlumberger; Xavier Bertagna; Pierre-François Plouin; Xavier Jeunemaitre; Anne-Paule Gimenez-Roqueplo
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

Review 9.  Paraganglioma in Pregnancy: A Case Series and Review of the Literature.

Authors:  Laurie A Wing; John V Conaglen; Goswin Y Meyer-Rochow; Marianne S Elston
Journal:  J Clin Endocrinol Metab       Date:  2015-06-17       Impact factor: 5.958

10.  When should genetic testing be obtained in a patient with phaeochromocytoma or paraganglioma?

Authors:  Zoran Erlic; Hartmut P H Neumann
Journal:  Clin Endocrinol (Oxf)       Date:  2008-12-03       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.